About
Technology
Issues
FAQ
Links
Official Page
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.